RT Journal Article
SR Electronic
T1 The unmitigated profile of COVID-19 infectiousness
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.17.21266051
DO 10.1101/2021.11.17.21266051
A1 Sender, Ron
A1 Bar-On, Yinon M.
A1 Park, Sang Woo
A1 Noor, Elad
A1 Dushoff, Jonathan
A1 Milo, Ron
YR 2021
UL http://medrxiv.org/content/early/2021/11/25/2021.11.17.21266051.abstract
AB Quantifying the temporal dynamics of infectiousness of individuals infected with SARS-CoV-2 is crucial for understanding the spread of the COVID-19 pandemic and for analyzing the effectiveness of different mitigation strategies. Many studies have tried to use data from the onset of symptoms of infector-infectee pairs to estimate the infectiousness profile of SARS-CoV-2. However, both statistical and epidemiological biases in the data could lead to an underestimation of the duration of infectiousness. We correct for these biases by curating data from the initial outbreak of the pandemic in China (when mitigation steps were still minimal), and find that the infectiousness profile is wider than previously thought. For example, our estimate for the proportion of transmissions occurring 14 days or more after infection is an order of magnitude higher - namely 19% (95% CI 10%-25%). The inferred generation interval distribution is sensitive to the definition of the period of unmitigated transmission, but estimates that rely on later periods are less reliable due to intervention effects. Nonetheless, the results are robust to other factors such as the model, the assumed growth rate and possible bias of the dataset. Knowing the unmitigated infectiousness profile of infected individuals affects estimates of the effectiveness of self-isolation and quarantine of contacts. The framework presented here can help design better quarantine policies in early stages of future epidemics using data from the initial stages of transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBen B. and Joyce E. Eisenberg Foundation, The Weizmann CoronaVirus Fund (R.M.), the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center, and by a research grant from the Estate of Tully and Michele Plesser (R.S.). R.M. is the Charles and Louise Gartner Professional Chair. Jonathan Dushoff is supported by the Canadian Institutes of Health Research. Y.M.B. is an Azrieli FellowAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://gitlab.com/milo-lab-public/the-unmitigated-profile-of-covid-19-infectiousness https://gitlab.com/milo-lab-public/the-unmitigated-profile-of-covid-19-infectiousness